San Diego’s life sciences community experienced an early December flurry of deals over the past week, led by Optimer, Volcano, Avelas Bio, and Biomatrica. We’ve got that and more.
—Optimer Pharmaceuticals (Nasdaq: OPTR), which recently opened a new headquarters in Jersey City, NJ, said it had signed an agreement with AstraZeneca to commercialize Optimer’s fidaxomicin tablets in South America. The deal could be worth as much as $23 million for Optimer, which developed fidaxomicin to treat diarrhea caused by Clostridium difficile infections. The company says its corporate headquarters and R&D laboratory are still in San Diego, and Jersey City is only Optimer’s new commercial headquarters. CEO Pedro Lichtinger lives in the New York City area, according to his LinkedIn profile.
—San Diego medical device maker Volcano Corp. (Nasdaq: VOLC), which specializes in devices used in the diagnosis and treatment of coronary and peripheral vascular disease, agreed to pay at least $36 million to acquire Menlo Park, CA-based Crux Biomedical. Crux has developed an innovative inferior vena cava (IVC) filter, used to treat pulmonary embolisms—a type of blockage typically caused by a blood clot that has broken free.
—San Diego-based Avelas Biosciences, a three-year-old biotech developing fluorescing peptides for use in cancer diagnostics, closed on a $7.65 million round of Series A funding, raised … Next Page »